A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
This study is a long-term follow-up for people who have received a special type of cell therapy called CRISPR CAR T. This treatment is used for certain blood (haematologic) cancers and solid tumours. The main goal is to understand how safe and effective the CRISPR CAR T therapy is over a long period, up to 15 years after treatment. Patients who were part of an earlier study involving this treatment and have completed it, or left it early, are being invited to join. By collecting information over many years, researchers hope to gain a better understanding of the lasting benefits and any potential side effects of this innovative cancer treatment. This will help improve future care for patients.
At a glance
What is this study about?
This study is all about understanding the long-term effects of a cutting-edge cancer treatment known as CRISPR CAR T-cell therapy. Imagine your body's immune cells as soldiers fighting off invaders. CAR T-cell therapy involves taking some of your own, or sometimes a donor's, immune cells (T-cells), and training them in a lab to better recognise and attack cancer cells. CRISPR is a technology used to make very precise changes to these cells to make them even more effective.
This particular study isn't about giving new treatment; it's about checking in with people who have already had this CRISPR CAR T-cell therapy for blood cancers or solid tumours. Researchers want to follow these individuals for a very long time – up to 15 years after their treatment. The main reasons for this long-term check-up are to see how safe the treatment continues to be over time and how well it has worked in the long run.
By carefully collecting information from many people over many years, the researchers hope to build a clearer picture of the lasting impact of this advanced therapy. This valuable information will help doctors and scientists learn more about CRISPR CAR T-cell treatments, understand any potential late effects, and ultimately, improve how these therapies are used to help future patients battling cancer.
Key takeaways
- This study is for long-term health checks after CRISPR CAR T therapy.
- It helps doctors understand the treatment's safety and effectiveness over many years.
- You won't receive new treatment; it's about monitoring your health.
- Participation involves regular check-ups and tests.
- It's open to adults (18+) who previously had this specific therapy.
- Your contribution helps improve future cancer care.
Who may be eligible?
To be able to join this study, you must be 18 years old or older. The most important requirement is that you have previously received the CRISPR CAR T cellular therapy as part of an earlier study.
You should also be able to understand what the study involves and be willing to give your agreement, in writing, to take part. There are no specific reasons why someone would be excluded from this long-term follow-up study, which means if you meet the main criteria, you're likely to be able to participate.
Both men and women are welcome to join this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you previously received CRISPR CAR T cellular therapy?
- Can you understand what the study involves and are you willing to sign a consent form?
- Are you able to attend follow-up appointments?
- Are you interested in helping researchers learn more about long-term treatment effects?
What does participation involve?
If you decide to take part in this study, you won't be receiving new treatment. Instead, you'll be participating in a long-term follow-up to check on your health after your previous CRISPR CAR T cellular therapy. This will involve regular check-ups, which will likely include physical examinations, blood tests, and possibly other scans or tests, as needed. The details of these visits and tests will be explained to you fully. The study aims to follow participants for a very long time, up to 15 years after they received their initial treatment. You'll continue to see your doctors and receive any standard medical care you need during this time.
Potential risks and benefits
Locations (22)
- City of HopeVerified postcodeDuarte, United States
- Cedars SinaiVerified postcodeLos Angeles, United States
- StanfordVerified postcodeStanford, United States
- Yale New Haven HospitalVerified postcodeNew Haven, United States
- EmoryVerified postcodeAtlanta, United States
- University of ChicagoVerified postcodeChicago, United States
- University of KansasVerified postcodeWestwood, United States
- University of MinnesotaVerified postcodeMinneapolis, United States
- Washington University Saint LouisVerified postcodeSt Louis, United States
- MSKCCVerified postcodeNew York, United States
- Montefiore Medical CenterVerified postcodeThe Bronx, United States
- Oregon Health and Science UniversityVerified postcodePortland, United States
Common questions
What is CRISPR CAR T cellular therapy?
It's a special type of cancer treatment where your own or donor immune cells are modified to find and destroy cancer cells more effectively.
Why is this study looking at people for so long?
Researchers want to understand the lasting effects, both good and bad, of the treatment over many years to make it better for future patients.
Will I receive any new treatment if I join this study?
No, this study is only for monitoring your health after you've already had the CRISPR CAR T therapy. You won't receive new treatment as part of this study.
What kind of visits will I have?
You'll have regular check-ups, which might include physical exams and blood tests, similar to what you might already do with your general doctor or hospital visits.
Can I leave the study if I change my mind?
Yes, absolutely. You can withdraw from the study at any point without any impact on your ongoing medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.